כלכלה · סיקור מלא

Israeli Pharma Company Teva Beats Expectations and Raises 2026 Revenue Forecast

איך 3 חדרי חדשות ישראליים סיפרו את הסיפור הזה, זה לצד זה.

Right 1Unrated 2

מאת אליהו עמר

דווח לראשונה בGlobes · יולי 29, 2026

מה קרה

Teva Pharmaceutical Industries reported stronger-than-expected Q2 2026 results, raising its revenue forecast for the year and boosting its stock by 12%. Despite a slight revenue decline due to generic drug sales drops, growth in innovative original drugs like Austedo and Ajovy drove optimism. The company posted a net loss mainly from a one-time acquisition charge but showed a small operational profit excluding this expense.

01Teva's Q2 2026 revenue reached $4.1 billion, beating analyst expectations despite a slight year-over-year decline.
02Loss of exclusivity on generic cancer drug Revlimid led to lower generic drug sales in the U.S.
03Sales of original drugs Austedo, Ajovy, and Uzedy grew significantly, driving revenue growth.
04Teva raised its 2026 sales forecast for these three drugs to $3.7 billion and upgraded full-year revenue guidance.
05The company reported a $576 million net loss due to a one-time acquisition charge but had a small operational profit excluding it.
06Investors responded positively, sending Teva's stock up about 12% at Wall Street opening.

התקציר תורגם וסוכם מהמקורות למטה על ידי baba. לקריאה המלאה פתחו כל מקור.

In this story